Advertisement
U.S. markets closed

Outlook Therapeutics, Inc. (OTLK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4480+0.0094 (+2.14%)
At close: 04:00PM EST
0.4525 +0.00 (+1.00%)
After hours: 07:27PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Engulfing Line (Bearish)

Engulfing Line (Bearish)

Previous Close0.4386
Open0.4368
Bid0.4440 x 1100
Ask0.4525 x 800
Day's Range0.4420 - 0.4550
52 Week Range0.2000 - 2.0300
Volume569,287
Avg. Volume2,068,696
Market Cap116.596M
Beta (5Y Monthly)0.02
PE Ratio (TTM)N/A
EPS (TTM)-0.2000
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.01
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for OTLK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Outlook Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 12/15/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GuruFocus.com

    Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments

    Financial and Corporate Milestones Highlighted Amidst Clinical Progress

  • GlobeNewswire

    Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

    NORSE EIGHT underway with first subject dosed and additional clinical sites beginning enrollment Continue to expect planned resubmission of the ONS-5010 Biologics License Application (BLA) by the end of CY2024 Anticipate review decision from European regulators in the first half of CY2024 ISELIN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first ophthalmic formulation of bevacizumab

  • GlobeNewswire

    Outlook Therapeutics® Doses First Subject in NORSE EIGHT

    NORSE EIGHT clinical trial is being conducted under Special Protocol Assessment (SPA) from FDA to support expected resubmission of the ONS-5010 Biologics License Application (BLA) by the end of CY2024, if successful ISELIN, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that the first subject has